EYPT vs RMNI Comparison

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. The company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management, database, and technology software systems. Geographically, the company generates its revenue from the United States of America and the International market.